OOIR: Observatory of International Research

Papers

(The median citation count of Current Opinion in Lipidology is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Regulation of lipoprotein lipase-mediated lipolysis of triglycerides	65
Remnant lipoproteins: are they equal to or more atherogenic than LDL?	55
Hypobetalipoproteinemia and abetalipoproteinemia: liver disease and cardiovascular disease	43
Genetic, biochemical, and clinical features of LCAT deficiency: update for 2020	36
ANGPTL3 as therapeutic target	33
Apolipoprotein C-II: the re-emergence of a forgotten factor	33
CD36 (SR-B2) as master regulator of cellular fatty acid homeostasis	29
Mendelian randomization as a tool for causal inference in human nutrition and metabolism	28
The next generation of triglyceride-lowering drugs: will reducing apolipoprotein C-III or angiopoietin like protein 3 reduce cardiovascular disease?	28
Familial combined hypolipidemia: angiopoietin-like protein-3 deficiency	28
Tangier disease: update for 2020	27
Very long-chain saturated fatty acids and diabetes and cardiovascular disease	26
Hypertriglyceridemia: new approaches in management and treatment	26
Update on apolipoprotein B	25
Impact of ultra-processed food consumption on metabolic health	24
Are dietary fish oil supplements appropriate for dyslipidemia management? A review of the evidence	23
Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia	22
Autosomal recessive hypercholesterolemia: update for 2020	22
Lipids and peripheral neuropathy	21
Management of familial hypercholesterolemia in pregnancy	20
Fibroblasts in atherosclerosis: heterogeneous and plastic participants	19
Transport of LDLs into the arterial wall: impact in atherosclerosis	19
Novel lecithin:cholesterol acyltransferase-based therapeutic approaches	18
Small dense low-density lipoprotein particles: clinically relevant?	17
Inborn errors of apolipoprotein A-I metabolism: implications for disease, research and development	17

The impact of race and ethnicity on lipoprotein(a) levels and cardiovascular risk	17
Advances, gaps and opportunities in the detection of familial hypercholesterolemia: overview of current and future screening and detection methods	17
Lipids and brain inflammation in APOE4-associated dementia	16
Measurement of carotid plaque burden	16
The clinical applicability of polygenic risk scores for LDL-cholesterol: considerations, current evidence and future perspectives	16
Characteristics of plaque lipid-associated macrophages and their possible roles in the pathogenesis of atherosclerosis	16
Dietary treatment to lower cholesterol and triglyceride and reduce cardiovascular risk	15
Extracellular matrix: paving the way to the newest trends in atherosclerosis	15
Evidence for improved survival with treatment of homozygous familial hypercholesterolemia	15
Consensus and guidelines on lipoprotein(a) – seeing the forest through the trees	14
Metabolic and cardiovascular outcomes of bariatric surgery	14
Depression and cardiovascular disease	14
Familial combined hyperlipidemia is a polygenic trait	13
Update on cerebrotendinous xanthomatosis	13
Lipid effects of glucagon-like peptide 1 receptor analogs	13
The iterative lipid impact on inflammation in atherosclerosis	13
Homozygous familial hypercholesterolemia: what treatments are on the horizon?	13
Small interfering RNA to proprotein convertase subtilisin/kexin type 9: transforming LDL-cholesterol-lowering strategies	13
Vascular stiffening and endothelial dysfunction in atherosclerosis	13
Triglyceride-rich lipoproteins, remnant-cholesterol, and atherosclerotic cardiovascular disease	13
Apolipoprotein F: a natural inhibitor of cholesteryl ester transfer protein and a key regulator of lipoprotein metabolism	13
Targeting epigenetics as atherosclerosis treatment: an updated view	13
Lipoprotein(a): is it more, less or equal to LDL as a causal factor for cardiovascular disease and mortality?	13
Understanding the ins and outs of lipoprotein (a) metabolism	12
The expanding role of lyso-phosphatidylcholine acyltransferase-3 (LPCAT3), a phospholipid remodeling enzyme, in health and disease	12
Familial hypercholesterolemia: is it time to separate monogenic from polygenic familial hypercholesterolemia?	11
The interconnection between lipoprotein(a), lipoprotein(a) cholesterol and true LDL-cholesterol in the diagnosis of familial hypercholesterolemia	11
Polygenic scores for dyslipidemia: the emerging genomic model of plasma lipoprotein trait inheritance	11
HDL and persistent inflammation immunosuppression and catabolism syndrome	11
Omega-3 fatty acids and cognitive function	11
The need for polygenic score reporting standards in evidence-based practice: lipid genetics use case	10
Angiopoietin-like proteins and postprandial partitioning of fatty acids	10
How should low-density lipoprotein cholesterol be calculated in 2022?	10
Dyslipidemia and aortic valve disease	10
Sphingosine-1-phosphate: metabolism, transport, atheroprotection and effect of statin treatment	10
Polygenic risk scores: how much do they add?	10
Age-associated arterial calcification: the current pursuit of aggravating and mitigating factors	10
Epigenetics of paraoxonases	10
Cardiovascular risk in patients with nonalcoholic fatty liver disease: looking at the liver to shield the heart	10
Can genetic testing help in the management of dyslipidaemias?	9
Atherosclerosis: cell biology and lipoproteins	9
When to lower triglycerides?	9
Nonalcohol fatty liver disease: balancing supply and utilization of triglycerides	9
Therapeutic application of genome editing in dyslipidemia	8
ANGPTL4: a new mode in the regulation of intravascular lipolysis	8
Recent advances in ABCG5 and ABCG8 variants	8
The role of gut-derived oxidized lipids and bacterial lipopolysaccharide in systemic inflammation and atherosclerosis	7
Role of VLDL receptor in atherogenesis	7
Reducing residual cardiovascular risk with novel therapies	7
New algorithms for treating homozygous familial hypercholesterolemia	7

The genetic counselor's role in management of patients with dyslipidemia	7
New insights in statins affecting atheromatous plaque macrophages	7
Proprotein convertase subtilisin/kexin type 9 inhibition after acute coronary syndrome or prior myocardial infarction	7
Lipid effects of sodium-glucose cotransporter 2 inhibitors	6
Dietary fat and carbohydrate affect the metabolism of protein-based high-density lipoprotein subspecies	6
Dietary factors and brain health	6
Translating guidelines into practice via implementation science: an update in lipidology	6
Cross-species data integration to prioritize causal genes in lipid metabolism	6
Evolving ANGPTL-based lipid-lowering strategies and beyond	6
Changing dietary approaches to prevent cardiovascular disease	6
Can we revive CETP-inhibitors for the prevention of cardiovascular disease?	6
Metabolic dysfunction-associated fatty liver disease: advances in genetic and epigenetic implications	6
The fish-oil paradox	5
Early atherogenesis: new insights from new approaches	5
Proprotein convertase subtilisin/kexin type 9 inhibition as the next statin?	5
Metabolic regulation of macrophage proliferation and function in atherosclerosis	5
Fatty liver and cerebrovascular disease: plausible association and possible mechanisms	5
Association of dietary patterns and components with atherosclerosis risk biomarkers in familial hypercholesterolemia	5
Deep dive to the secrets of the PREDIMED trial	5
Is it time to reconcile HDL with cardiovascular diseases and beyond? An update on a paradigm shift	4
Liver fat storage pathways: methodologies and dietary effects	4
Links between ceramides and cardiac function	4
Impact of metabolic dysfunction on cognition in humans	4
Macrophage SR-B1 in atherosclerotic cardiovascular disease	4
Recent Apolipoprotein CIII trials	4
Using the electronic health record for genomics research	4
Sphingomyelins and ceramides: possible biomarkers for dementia?	4
Considerations for routinely testing for high Lp(a)	4
Editorial: Discussing polygenic risk with lipid clinic patients	4
Use of apheresis in the age of new therapies for familial hypercholesterolaemia	4
Current models of apolipoprotein A-I lipidation by adenosine triphosphate binding cassette transporter A1	4
The role of the molecular circadian clock in human energy homeostasis	4
Inclisiran: present and future perspectives of a new effective LDL cholesterol-lowering agent	4
Recent lipoprotein(a) trials	4
Cascade screening for familial hypercholesterolemia should be organized at a national level	3
Angiopoietin-like protein 3 inhibitors and contemporary unmet needs in lipid management	3
Non-HDL or LDL cholesterol in heterozygous familial hypercholesterolaemia: findings of the Simon Broome Register	3
Lymphatics - not just a chylomicron conduit	3
Editorial: Nitro-fatty acids: novel drug candidates for the co-treatment of atherosclerosis and nonalcoholic fatty liver disease	3
Recent dynamic studies of the metabolism of atherogenic lipoproteins: elucidating the mode of action of new therapies	3
The interplay between serum amyloid A and HDLs	3
Lipidomics in gestational diabetes mellitus	3
Inflammation compared to low-density lipoprotein cholesterol: two different causes of atherosclerotic cardiovascular disease	3
Genetic variants associated with cardiovascular diseases and related risk factors highlight novel potential therapeutic approaches	3
LDL receptor-related protein 1 and its interacting partners in tissue homeostasis	3
Editorial comment: when Mendelian randomization goes astray	3
Genetic determinants of pancreatitis: relevance in severe hypertriglyceridemia	3
Metabolism of lipoprotein(a): new findings, implications and outstanding issues	3
Soy consumption, cognitive function, and dementia	3
Angiopoietin-like 3 inhibition and the liver: less is more?	3
The power of lipid registries for cardiovascular disease prevention	3